Considerations in the approach to invasive fungal infection in patients with haematological malignancies

British Journal of Haematology

Volumn 140, Issue 2, 2008, Pages 133-152

  Bow, Eric J ^a,b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Infection Control Unit   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Directed therapy; Empirical therapy; Invasive fungal infection; Pre emptive therapy; Prophylaxis

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTHRACYCLINE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; CORTICOSTEROID; CYTARABINE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FLUDARABINE; INFLIXIMAB; ITRACONAZOLE; MICAFUNGIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; DIAGNOSTIC TEST; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; LEUKEMIA; MORBIDITY; MORTALITY; MOULD; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; YEAST;

ANTIFUNGAL AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; MYCOSES; OPPORTUNISTIC INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 37349063145     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06906.x     Document Type: Review

References (178)

1. Abele-Horn, M., Kopp, A., Sternberg, U., Ohly, A., Dauber, A., Russwurm, W., Buchinger, W., Nagengast, O. Emmerling, P. (1996) A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection, 24, 426 432.
2. Alexander, B.D., Schell, W.A., Miller, J.L., Long, G.D. Perfect, J.R. (2005) Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation, 80, 868 871.
3. Aliff, T.B., Maslak, P.G., Jurcic, J.G., Heaney, M.L., Cathcart, K.N., Sepkowitz, K.A. Weiss, M.A. (2003) Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin 6. Cancer, 97, 1025 1032.
4. Anaissie, E.J., Darouiche, R.O., Abi-Said, D., Uzun, O., Mera, J., Gentry, L.O., Williams, T., Kontoyiannis, D.P., Karl, C.L. Bodey, G.P. (1996) Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clinical Infectious Diseases, 23, 964 972.
5. Anaissie, E.J., Rex, J.H., Uzun, O. Vartivarian, S. (1998) Predictors of adverse outcome in cancer patients with candidemia. American Journal of Medicine, 104, 238 245.
6. Ascioglu, S., De Pauw, B.E., Donnelly, J.P. Collette, L. (2001) Reliability of clinical research on invasive fungal infections: a systematic review of the literature. Medical Mycology, 39, 35 40.
7. Ascioglu, S., Rex, J.H., de Pauw, B., Bennett, J.E., Bille, J., Crokaert, F., Denning, D.W., Donnelly, J.P., Edwards, J.E., Erjavec, Z., Fiere, D., Lortholary, O., Maertens, J., Meis, J.F., Patterson, T.F., Ritter, J., Selleslag, D., Shah, P.M., Stevens, D.A. Walsh, T.J. (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clinical Infectious Diseases, 34, 7 14.
8. Baddley, J.W., Stroud, T.P., Salzman, D. Pappas, P.G. (2001) Invasive mold infections in allogeneic bone marrow transplant recipients. Clinical Infectious Diseases, 32, 1319 1324.
9. Badia, X., Roset, M., Carreras, E., Ausin, I. Herrera, L. (2004) Meta-analysis on safety and efficacy of liposomal amphotericin B in the empirical treatment of febrile neutropenia. Medicina Clinica (BARC), 122, 610 616.
10. Barrett, J.P., Vardulaki, K.A., Conlon, C., Cooke, J., za-Ramirez, P., Evans, E.G., Hawkey, P.M., Herbrecht, R., Marks, D.I., Moraleda, J.M., Park, G.R., Senn, S.J. Viscoli, C. (2003) A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clinical Therapeutics, 25, 1295 1320.
11. Bates, D.W., Su, L., Yu, D.T., Chertow, G.M., Seger, D.L., Gomes, D.R., Dasbach, E.J. Platt, R. (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy. Clinical Infectious Diseases, 32, 686 693.
12. Bennett, J.E., Powers, J., Walsh, T., Viscoli, C., de, P.B., Dismukes, W., Galgiani, J., Glauser, M., Herbrecht, R., Kauffman, C., Lee, J., Pappas, P., Rex, J. Verweij, P. (2003) Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clinical Infectious Diseases, 36, S117 S122.
13. Betts, R., Glasmacher, A., Maertens, J., Maschmeyer, G., Vazquez, J.A., Teppler, H., Taylor, A., Lupinacci, R., Sable, C. Kartsonis, N. (2006) Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer, 106, 466 473.
14. Bhatti, Z., Shaukat, A., Almyroudis, N.G. Segal, B.H. (2006) Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia, 162, 1 15.
15. Blijlevens, N.M., Donnelly, J.P. De Pauw, B.E. (2002) Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. British Journal Haematology, 117, 259 264.
16. Bodey, G.P., Buckley, M., Sathe, Y.S. Freireich, E.J. (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine, 64, 328 340.
17. Bodey, G.P., Rodriguez, V., Chang, H.Y. Narboni, G. (1978) Fever and infection in leukemic patients:a study of 494 consecutive patients. Cancer, 41, 1610 1622.
18. Boogaerts, M., Winston, D.J., Bow, E.J., Garber, G., Reboli, A.C., Schwarer, A.P., Novitzky, N., Boehme, A., Chwetzoff, E. De Beule, K. (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Annals of Internal Medicine, 135, 412 422.
19. Bow, E.J. (2005) Assessment of the risk for invasive fungal infection among oncology patients. In : Fungal Infections in the Immunocompromised Patient (ed. by J.R. Wingard E.J. Anaissie pp. 97 128. Taylor & Francis Group, Boca Raton, FL.
20. Bow, E.J. (2006) Of yeasts and hyphae: a hematologist's approach to antifungal therapy. Hematology/the Education Program of the American Society of Hematology, 361 367.
21. Bow, E.J. Louie, T.J. (1987) Changes in endogenous microflora among febrile granulocytopenic patients receiving empiric antibiotic therapy: implications for fungal superinfection. Canadian Medical Association Journal, 137, 397 403.
22. Bow, E.J., Kilpatrick, M.G., Scott, B.A., Clinch, J.J. Cheang, M.S. (1994) Acute myeloid leukemia in Manitoba. The consequences of standard '7 + 3' remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome. Cancer, 74, 52 60.
23. Bow, E.J., Loewen, R., Cheang, M.S. Schacter, B. (1995) Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clinical Infectious Diseases, 21, 361 369.
24. Bow, E.J., Sutherland, J.A., Kilpatrick, M.G., Williams, G.J., Clinch, J.J., Shore, T.B., Rubinger, M. Schacter, B.A. (1996) Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. Journal of Clinical Oncology, 14, 1345 1352.
25. Bow, E.J., Gallant, G., Williams, G.J., Woloschuk, D., Shore, T.B., Rubinger, M. Schacter, B.A. (1998) Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide and carboplatin. Cancer, 83, 1344 1354.
26. Bow, E.J., Laverdière, M. Rotstein, C. (2000) A systematic review of the efficacy of azoles and lipid-based formulations of amphotericin B as empirical anti-fungal therapy in persistently febrile neutropenic patients despite broad-spectrum anti-bacterial therapy. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 364 (Abstract no. 702).
27. Bow, E.J., Laverdiere, M., Lussier, N., Rotstein, C., Cheang, M.S. Ioannou, S. (2002) Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer, 94, 3230 3246.
28. Caillot, D., Casasnovas, O., Bernard, A., Couaillier, J.F., Durand, C., Cuisenier, B., Solary, E., Piard, F., Petrella, T., Bonnin, A., Couillault, G., Dumas, M. Guy, H. (1997) Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. Journal of Clinical Oncology, 15, 139 147.
29. Chamilos, G. Kontoyiannis, D.P. (2006) Defining the diagnosis of invasive aspergillosis. Medical Mycology, 44 (Suppl. 163 172.
30. Chamilos, G., Luna, M., Lewis, R.E., Bodey, G.P., Chemaly, R., Tarrand, J.J., Safdar, A., Raad, I.I. Kontoyiannis, D.P. (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica, 91, 986 989.
31. Chandrasekar, P.H. Ito, J.I. (2005) Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clinical Infectious Diseases, 40 (Suppl. 6 S392 S400.
32. Chen, S., Slavin, M., Nguyen, Q., Marriott, D., Playford, E.G., Ellis, D. Sorrell, T. (2006) Active surveillance for candidemia, Australia. Emerging Infectious Diseases, 12, 1508 1516.
33. Clancy, C.J., Yu, V.L., Morris, A.J., Snydman, D.R. Nguyen, M.H. (2005) Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrobial Agents and Chemotherapy, 49, 3171 3177.
34. Cordonnier, C., Pautas, C., Maury, S., Vekhoff, A., Farhat, H., Suarez, F., Basile, M., Isnard, F., Ades, L., Kuhnoski, F., Reman, O., Chehata, S., De Revel, T., Lepretre, S., Raffoux, E., Bretagne, S. Schwarzinger, M. (2006) Empirical versus pre-emptive antifungal therapy in high-risk febrile neutropenic patients: a prospective randomized study. Blood (ASH Annual Meeting Abstracts), 108, 2019.
35. Cordonnier, C., Bresnik, M. Ebrahimi, R. (2007) Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis. Mycoses, 50, 205 209.
36. Corey, L. Boeckh, M. (2002) Persistent fever in patients with neutropenia. The New England Journal of Medicine, 346, 222 224.
37. Cornely, O.A., Bohme, A., Buchheidt, D., Glasmacher, A., Kahl, C., Karthaus, M., Kern, W., Kruger, W., Maschmeyer, G., Ritter, J., Salwender, H.J., Sandherr, M., Schiel, X., Schuttrumpf, S., Sieniawski, M., Silling, G., Ullmann, A.J. Wolf, H.H. (2003) Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology, 82 (Suppl. 2 S186 S200.
38. Cornely, O.A., Maertens, J., Winston, D.J., Perfect, J., Ullmann, A.J., Walsh, T.J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.T., Petrini, M., Hardalo, C., Suresh, R. Ngulo-Gonzalez, D. (2007a) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. The New England Journal of Medicine, 356, 348 359.
39. Cornely, O.A., Maertens, J., Bresnik, M., Ebrahimi, R., Ullmann, A.J., Bouza, E., Heussel, C.P., Lortholary, O., Rieger, C., Boehme, A., Aoun, M., Horst, H.A., Thiebaut, A., Ruhnke, M., Reichert, D., Vianelli, N., Krause, S.W., Olavarria, E. Herbrecht, R. (2007b) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clinical Infectious Diseases, 44, 1289 1297.
40. Couriel, D., Saliba, R., Hicks, K., Ippoliti, C., de, L.M., Hosing, C., Khouri, I., Andersson, B., Gajewski, J., Donato, M., Anderlini, P., Kontoyiannis, D.P., Cohen, A., Martin, T., Giralt, S. Champlin, R. (2004) Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood, 104, 649 654.
41. Cruciani, M., Mengoli, C., Malena, M., Bosco, O., Serpelloni, G. Grossi, P. (2006) Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transplantation, 12, 850 858.
42. De Pauw, B.E. (2005) Between over- and undertreatment of invasive fungal disease. Clinical Infectious Diseases, 41, 1251 1253.
43. De Pauw, B.E. Patterson, T.F. (2005) Should the consensus guidelines' specific criteria for the diagnosis of invasive fungal infection be changed? Clinical Infectious Diseases, 41 (Suppl. 6 S377 S380.
44. Denning, D.W. (2003) Echinocandin antifungal drugs. Lancet, 362, 1142 1151.
45. Denning, D.W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M. Lode, H. (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clinical Infectious Diseases, 34, 563 571.
46. Denning, D.W., Kibbler, C.C. Barnes, R.A. (2003) British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. The Lancet Infectious Diseases, 3, 230 240.
47. Donnelly, J.P. (2006) Consensus definitions for invasive fungal disease: strengths, limitations, and revisions. Medical Mycology, 44 (Suppl. 285 288.
48. Dykewicz, C.A. (2001) Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clinical Infectious Diseases, 33, 139 144.
49. Dykewicz, C.A., Jaffe, H.A. Kaplan, J.E. (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biology of Blood and Marrow Transplantation, 6, 659 713.
50. Ellis, D. (2002) Amphotericin B: spectrum and resistance. Journal of Antimicrobial Chemotherapy, 49 (Suppl. 1 7 10.
51. Ellis, M.E., Halim, M.A., Spence, D., Ernst, P., Clink, H., Kalin, M., Baillie, F. Greer, W. (1995) Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever - preliminary observations from a pilot, exploratory study. Journal of Infection, 30, 141 146.
52. EORTC International Antimicrobial Therapy Project Group (1989) Empiric antifungal therapy in febrile granulocytopenic patients. American Journal of Medicine, 86, 668 672.
53. Fleck, R., Dietz, A. Hof, H. (2007) In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. Journal of Antimicrobial Chemotherapy, 59, 767 771.
54. Freifeld, A.G., Baden, L.R., Brown, A.E., Elting, L., Gelfand, M., Greene, J.N., Ito, J.I., King, E., Marucci, G., Montoya, J.G., Morris, A., Noskin, G., Rolston, K., Schott, A.F. Segal, B.H. (2004) Fever and neutropenia. Journal of the National Comprehensive Cancer Network, 2, 390 432.
55. Freifeld, A.G., Segal, B.H., Baden, L.R., Brown, A.E., Caspar, C., deShazzo, M., Dubberke, E., Elting, L.S., Gelfand, M., Greene, J.N., Ison, M.G., Ito, J.I., Karp, J.E., Kaul, D.R., King, E., Mackler, E., Marcucci, G., Montoya, J.G., Morris, A. Rolston, K. (2007) Prevention and treatment of cancer-related infections. National Comprehensive Cancer Network - clinical practice guidelines in oncology v2. 2007. http://www.nccn.org/professionals/ physician_gls/PDF/infections.pdf accessed 4 September 2007.
56. Fukuda, T., Boeckh, M., Carter, R.A., Sandmaier, B.M., Maris, M.B., Maloney, D.G., Martin, P.J., Storb, R.F. Marr, K.A. (2003) Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood, 102, 827 833.
57. Furrer, H., Egger, M., Opravil, M., Bernasconi, E., Hirschel, B., Battegay, M., Telenti, A., Vernazza, P.L., Rickenbach, M., Flepp, M. Malinverni, R. (1999) Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. New England Journal of Medicine, 340, 1301 1306.
58. Furrer, H., Opravil, M., Rossi, M., Bernasconi, E., Telenti, A., Bucher, H., Schiffer, V., Boggian, K., Rickenbach, M., Flepp, M. Egger, M. (2001) Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. AIDS, 15, 501 507.
59. Garey, K.W., Pai, M.P., Suda, K.J., Turpin, R.S., Rege, M.D., Mingo, D.E. Bearden, D.T. (2007) Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiology and Drug Safety, 16, 919 927.
60. Girois, S.B., Chapuis, F., Decullier, E. Revol, B.G. (2005) Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. European Journal of Clinical Microbiology and Infectious Diseases, 24, 119 130.
61. Glasmacher, A. Prentice, A.G. (2005) Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. Journal of Antimicrobial Chemotherapy, 56 (Suppl. 1 i23 i32.
62. Glasmacher, A., Prentice, A., Gorschluter, M., Engelhart, S., Hahn, C., Djulbegovic, B. Schmidt-Wolf, I.G. (2003) Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3, 597 patients. Journal of Clinical Oncology, 21, 4615 4626.
63. Glasmacher, A., Hahn, C., von Lilienfeld-Toal, M., Orlopp, K., Schmidt-Wolf, I. Prentice, A. (2005) Itraconazole for antifungal prophylaxis in neutropenic patients: an update of a meta-analysis with now 3846 patients. Blood (ASH Annual Meeting Abstracts), 106, 3224.
64. Glasmacher, A., Cornely, O., Ullmann, A.J., Wedding, U., Bodenstein, H., Wandt, H., Boewer, C., Pasold, R., Wolf, H.H., Hanel, M., Dolken, G., Junghanss, C., Andreesen, R. Bertz, H. (2006) An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. Journal of Antimicrobial Chemotherapy, 57, 317 325.
65. Goodman, J.L., Winston, D.J., Greenfield, R.A., Chandrasekar, P.H., Fox, B., Kaizer, H., Shadduck, R.K., Shea, T.C., Stiff, P., Friedman, D.J. (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine, 326, 845 851.
66. Greenberg, R.N., Mullane, K., van Burik, J.A., Raad, I., Abzug, M.J., Anstead, G., Herbrecht, R., Langston, A., Marr, K.A., Schiller, G., Schuster, M., Wingard, J.R., Gonzalez, C.E., Revankar, S.G., Corcoran, G., Kryscio, R.J. Hare, R. (2006) Posaconazole as salvage therapy for zygomycosis. Antimicrobial Agents and Chemotherapy, 50, 126 133.
67. Greene, R.E., Schlamm, H.T., Oestmann, J.W., Stark, P., Durand, C., Lortholary, O., Wingard, J.R., Herbrecht, R., Ribaud, P., Patterson, T.F., Troke, P.F., Denning, D.W., Bennett, J.E., De Pauw, B.E. Rubin, R.H. (2007) Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clinical Infectious Diseases, 44, 373 379.
68. Harbarth, S., Pestotnik, S.L., Lloyd, J.F., Burke, J.P. Samore, M.H. (2001) The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. American Journal of Medicine, 111, 528 534.
69. Harbarth, S., Burke, J.P., Lloyd, J.F., Evans, R.S., Pestotnik, S.L. Samore, M.H. (2002) Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clinical Infectious Diseases, 35, e120 e127.
70. Hebart, H., Klingspor, L., Klingebiehl, T., Loeffler, J., Tollemar, J., Ljungman, P., Wandt, H., Dornbusch, H.J., Schumacher, U., Meisner, C., Engel, C., Kanz, L., Ringden, O. Einsele, H. (2004) PCR-based liposomal amphotericin B treatment following allogeneic stem cell transplantation is a safe treatment strategy: preliminary results of a prospective study. Blood (ASH Annual Meeting Abstracts), 104, 192.
71. Herbrecht, R., Denning, D.W., Patterson, T.F., Bennett, J.E., Greene, R.E., Oestmann, J.W., Kern, W.V., Marr, K.A., Ribaud, P., Lortholary, O., Sylvester, R., Rubin, R.H., Wingard, J.R., Stark, P., Durand, C., Caillot, D., Thiel, E., Chandrasekar, P.H., Hodges, M.R., Schlamm, H.T., Troke, P.F. de Pauw, B. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine, 347, 408 415.
72. Herbrecht, R., Fluckiger, U., Gachot, B., Ribaud, P., Thiebaut, A. Cordonnier, C. (2007) Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. European Journal of Cancer (Supplements), 5, 49 59.
73. Heussel, C.P., Kauczor, H.U., Heussel, G.E., Fischer, B., Begrich, M., Mildenberger, P. Thelen, M. (1999) Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. Journal of Clinical Oncology, 17, 796 805.
74. Holding, K.J., Dworkin, M.S., Wan, P.C., Hanson, D.L., Klevens, R.M., Jones, J.L. Sullivan, P.S. (2000) Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and adolescent spectrum of HIV disease project. Clinical Infectious Diseases, 31, 1253 1257.
75. ®: a comprehensive, prospective registry of patients with invasive fungal infections. Focus on Fungal Infections 16 (Las Vegas, March 6-10), Presentation Summaries and Abstracts, Focus on Fungal Infections 16 (Las Vegas, March 6-10 184 (Abstract P-024).
76. Hughes, W.T., Armstrong, D., Bodey, G.P., Bow, E.J., Brown, A.E., Calandra, T., Feld, R., Pizzo, P.A., Rolston, K.V.I., Shenep, J.L. Young, L.S. (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases, 34, 730 751.
77. Imataki, O., Kami, M., Kim, S.W., Gotoh, M., Komaba, S., Kasai, M., Hashino, S., Naito, K., Masuda, M., Anan, K., Teshima, H., Togitani, K., Inoue, T., Nishimura, M., Adachi, Y., Fukuhara, T., Yamashita, T., Uike, N., Kobayashi, Y., Hamaguchi, M., Higuchi, M., Kawakami, K. Takaue, Y. (2004) A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan. Bone Marrow Transplantation, 33, 1173 1179.
78. Jansen, J.P., Meis, J.F., Blijlevens, N.M. van't Wout, J.W. (2005) Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Current Medical Research and Opinion, 21, 1535 1546.
79. Jansen, J.P., Kern, W.V., Cornely, O.A., Karthaus, M., Ruhnke, M., Ullmann, A.J. Resch, A. (2006) Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health, 9, 12 23.
80. Kanda, Y., Yamamoto, R., Chizuka, A., Hamaki, T., Suguro, M., Arai, C., Matsuyama, T., Takezako, N., Miwa, A., Kern, W., Kami, M., Akiyama, H., Hirai, H. Togawa, A. (2000) Prophylactic action of oral fluconazole against infection in neutropenic patients - a meta-analysis of 16 randomized, controlled trials. Cancer, 89, 1611 1625.
81. Kartsonis, N.A., Saah, A.J., Joy, L.C., Taylor, A.F. Sable, C.A. (2005) Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. Journal of Infection, 50, 196 205.
82. Kish, M.A. (2001) Guide to development of practice guidelines. Clinical Infectious Diseases, 32, 851 854.
83. Klastersky, J. (2004a) Antifungal therapy in patients with fever and neutropenia - more rational and less empirical New England Journal of Medicine, 351, 1445 1447.
84. Klastersky, J. (2004b) Empirical antifungal therapy. International Journal of Antimicrobial Agents, 23, 105 112.
85. Klastersky, J. (2006) Adverse effects of the humanized antibodies used as cancer therapeutics. Current Opinion in Oncology, 18, 316 320.
86. Kontoyiannis, D.P., Hachem, R., Lewis, R.E., Rivero, G.A., Torres, H.A., Thornby, J., Champlin, R., Kantarjian, H., Bodey, G.P. Raad, I.I. (2003) Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer, 98, 292 299.
87. Kontoyiannis, D.P., Boktour, M., Hanna, H., Torres, H.A., Hachem, R. Raad, I.I. (2005) Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer, 103, 2334 2337.
88. Kullberg, B.J., Sobel, J.D., Ruhnke, M., Pappas, P.G., Viscoli, C., Rex, J.H., Cleary, J.D., Rubinstein, E., Church, L.W., Brown, J.M., Schlamm, H.T., Oborska, I.T., Hilton, F. Hodges, M.R. (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet, 366, 1435 1442.
89. Kuse, E.R., Chetchotisakd, P., da Cunha, C.A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J.S., Freire, A., Ramasubramanian, V., Demeyer, I., Nucci, M., Leelarasamee, A., Jacobs, F., Decruyenaere, J., Pittet, D., Ullmann, A.J., Ostrosky-Zeichner, L., Lortholary, O., Koblinger, S., ekmann-Berndt, H. Cornely, O.A. (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet, 369, 1519 1527.
90. Lazarus, H.M., Lowder, J.N., Anderson, J.M. Herzig, R.H. (1984) A prospective randomized trial of central venous catheter removal versus intravenous amphotericin B in febrile neutropenic patients. Journal of Parenteral and Enteral Nutrition, 8, 501 505.
91. Leenders, A.C.A.P., Daenen, S., Jansen, R.L.H., Hop, W.C.J., Lowenberg, B., Wijermans, P.W., Cornelissen, J., Herbrecht, R., Van der Lelie, H., Hoogsteden, H.C., Verbrugh, H.A. De Marie, S. (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documanted and suspected neutropenia-associated invasive fungal infection. British Journal of Haematology, 103, 205 212.
92. Levine, S.J. (1992) An approach to the diagnosis of pulmonary infections in immunosuppressed patients. Seminars in Respiratory Infections, 7, 81 95.
93. Link, H., Bohme, A., Cornely, O.A., Hoffken, K., Kellner, O., Kern, W.V., Mahlberg, R., Maschmeyer, G., Nowrousian, M.R., Ostermann, H., Ruhnke, M., Sezer, O., Schiel, X., Wilhelm, M. Auner, H.W. (2003) Antimicrobial therapy of unexplained fever in neutropenic patients - Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Annals of Hematology, 82 (Suppl. 2 S105 S117.
94. Maertens, J. (2007) Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. European Journal of Haematology, 78, 275 282.
95. Maertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F.B., Sable, C.A., Kartsonis, N.A., Ngai, A., Taylor, A., Patterson, T.F., Denning, D.W. Walsh, T.J. (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clinical Infectious Diseases, 39, 1563 1571.
96. Maertens, J., Theunissen, K., Verhoef, G., Verschakelen, J., Lagrou, K., Verbeken, E., Wilmer, A., Verhaegen, J., Boogaerts, M. Van, E.J. (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clinical Infectious Diseases, 41, 1242 1250.
97. Maertens, J., Theunissen, K., Deeren, D., Meersseman, W. Van, E.J. (2006a) Defining a case of invasive aspergillosis by serum galactomannan. Medical Mycology, 44 (Suppl. 173 178.
98. Maertens, J., Glasmacher, A., Herbrecht, R., Thiebaut, A., Cordonnier, C., Segal, B.H., Killar, J., Taylor, A., Kartsonis, N., Patterson, T.F., Aoun, M., Caillot, D. Sable, C. (2006b) Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer, 107, 2888 2897.
99. Maertens, J.A., Frere, P., Lass-Florl, C., Heinz, W. Cornely, O.A. (2007) Primary antifungal prophylaxis in leukaemia patients. European Journal of Cancer (Supplements), 5, 43 48.
100. Malik, I.A., Moid, I., Aziz, Z., Khan, S. Suleman, M. (1998) A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. American Journal of Medicine, 105, 478 483.
101. Marchetti, O., Cordonnier, C. Calandra, T. (2007) Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. European Journal of Cancer (Supplements), 5, 32 42.
102. Marie, J.P., Lapierre, V., Pico, J., Vekhoff, A., Molina, L., Andremont, A., Basset, D., Lebeau, R., Michalet, M., Zittoun, R. Hayat, M. (1993) Randomised multicentre trial of intravenous fluconazole versus intravenous amphotericin B in neutropenic febrile patients. Cahiers Oncologie, 2, 171 173.
103. Marr, K.A. (2002) Empirical antifungal therapy - new options, new tradeoffs. New England Journal of Medicine, 346, 278 280.
104. Marr, K.A., Seidel, K., Slavin, M.A., Bowden, R.A., Schoch, H.G., Flowers, M.E.D., Corey, L. Boeckh, M. (2000) Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood, 96, 2055 2061.
105. Marr, K.A., Carter, R.A., Boeckh, M., Martin, P. Corey, L. (2002a) Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood, 100, 4358 4366.
106. Marr, K.A., Carter, R.A., Crippa, F., Wald, A. Corey, L. (2002b) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clinical Infectious Diseases, 34, 909 917.
107. Marr, K.A., Boeckh, M., Carter, R.A., Kim, H.W. Corey, L. (2004) Combination antifungal therapy for invasive aspergillosis. Clinical Infectious Diseases, 39, 797 802.
108. Martin, S.I., Marty, F.M., Fiumara, K., Treon, S.P., Gribben, J.G. Baden, L.R. (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clinical Infectious Diseases, 43, 16 24.
109. Martino, R. Viscoli, C. (2006) Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. British Journal Haematology, 132, 138 154.
110. Marty, F.M., Lee, S.J., Fahey, M.M., Alyea, E.P., Soiffer, R.J., Antin, J.H. Baden, L.R. (2003) Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood, 102, 2768 2776.
111. McLintock, L.A., Jordanides, N.E., Allan, E.K., Copland, M., Stewart, K., Parker, A., Devaney, M., Holyoake, T.L. Jones, B.L. (2004) The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. British Journal Haematology, 124, 403 404.
112. Mennink-Kersten, M.A., Donnelly, J.P. Verweij, P.E. (2004) Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. The Lancet Infectious Diseases, 4, 349 357.
113. Miller, C.B., Waller, E.K., Klingemann, H.G., Dignani, M.C., Anaissie, E.J., Cagnoni, P.J., McSweeney, P., Fleck, P.R., Fruchtman, S.M., McGuirk, J. Chao, N.J. (2004) Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplantation, 33, 543 548.
114. Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A.L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N. Perfect, J. (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. New England Journal of Medicine, 347, 2020 2029.
115. Morgan, J., Wannemuehler, K.A., Marr, K.A., Hadley, S., Kontoyiannis, D.P., Walsh, T.J., Fridkin, S.K., Pappas, P.G. Warnock, D.W. (2005) Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Medical Mycology, 43 (Suppl. 1 S49 S58.
116. National Cancer Institute & National Institutes of Health (1999) Cancer Therapy Evaluation Program, National Cancer Institute Common Toxicity Criteria Version 2.0. US Department of Health and Human Services, Bethesda.
117. Nucci, M. (2003) Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Current Opinion in Infectious Diseases, 16, 607 612.
118. Nucci, M., Colombo, A.L., Silveira, F., Richtmann, R., Salomao, R., Branchini, M.L. Spector, N. (1998) Risk factors for death in patients with candidemia. Infection Control and Hospital Epidemiology, 19, 846 850.
119. O'Hanley, P., Easaw, J., Rugo, H. Easaw, S. (1989) Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. American Journal of Medicine, 87, 605 613.
120. Pagano, L., Girmenia, C., Mele, L., Ricci, P., Tosti, M.E., Nosari, A., Buelli, M., Picardi, M., Allione, B., Corvatta, L., D'Antonio, D., Montillo, M., Melillo, L., Chierichini, A., Cenacchi, A., Tonso, A., Cudillo, L., Candoni, A., Savignano, C., Bonini, A., Martino, P. Del Favero, A. (2001) Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica, 86, 862 870.
121. Pagano, L., Caira, M., Candoni, A., Offidani, M., Fianchi, L., Martino, B., Pastore, D., Picardi, M., Bonini, A., Chierichini, A., Fanci, R., Caramatti, C., Invernizzi, R., Mattei, D., Mitra, M.E., Melillo, L., Aversa, F., Van Lint, M.T., Falcucci, P., Valentini, C.G., Girmenia, C. Nosari, A. (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the
122. Pagano, L., Caira, M., Picardi, M., Candoni, A., Melillo, L., Fianchi, L., Offidani, M. Nosari, A. (2007) Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality - SEIFEM-C report. Clinical Infectious Diseases, 44, 1524 1525.
123. Panackal, A.A., Gribskov, J.L., Staab, J.F., Kirby, K.A., Rinaldi, M. Marr, K.A. (2006) Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. Journal of Clinical Microbiology, 44, 1740 1743.
124. Pappas, P.G., Alexander, B., Marr, K., Kontoyianis, D.P., Hadley, S., Ito, J., Morrison, V.A., Morgan, J., Fridkin, S.K., Oster, R., Daram, P. Walsh, T.J. (2004a) Invasive fungal infections (IFIs) in hematopoietic stem cell (HSCTs) and organ transplant recipients (OTRs): Overview of the TRANSNET database. IDSA, Boston, pp. 174 (Abstract 671).
125. Pappas, P.G., Rex, J.H., Sobel, J.D., Filler, S.G., Dismukes, W.E., Walsh, T.J. Edwards, J.E. (2004b) Guidelines for treatment of candidiasis. Clinical Infectious Diseases, 38, 161 189.
126. Perfect, J.R. (2005) Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clinical Infectious Diseases, 40 (Suppl. 6 S401 S408.
127. Perfect, J.R., Klotman, M.E., Gilbert, C.C., Crawford, D.D., Rosner, G.L., Wright, K.A. Peters, W.P. (1992) Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. Journal of Infectious Diseases, 165, 891 897.
128. Perfect, J.R., Marr, K.A., Walsh, T.J., Greenberg, R.N., Dupont, B., de, l.T.-C., Just-Nubling, G., Schlamm, H.T., Lutsar, I., Espinel-Ingroff, A. Johnson, E. (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clinical Infectious Diseases, 36, 1122 1131.
129. Pfaller, M.A. Diekema, D.J. (2004) Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clinical Microbiology and Infection, 10 (Suppl. 1 11 23.
130. Pfaller, M.A. Diekema, D.J. (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clinical Microbiology Reviews, 20, 133 163.
131. Pfaller, M.A., Pappas, P.G. Wingard, J.R. (2006) Invasive fungal pathogens: current epidemiological trends. Clinical Infectious Diseases, 43, S3 S14.
132. Phillips, P., Shafran, S., Garber, G., Rotstein, C., Smaill, F., Fong, I., Salit, I., Miller, M., Williams, K., Conly, J.M., Singer, J. Ioannou, S. (1997) Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. European Journal of Clinical Microbiology and Infectious Diseases, 16, 337 345.
133. Pizzo, P.A., Robichaud, K.J., Gill, F.A. Witebsky, F.G. (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. American Journal of Medicine, 72, 101 111.
134. Postma, M.J., de Vries, R., Christopherson, H., Howells, S., Tolley, K., Daenen, S., Glasmacher, A., Prentice, A. Christie, A. (2005) Cost-effectiveness of itraconazole for the prophylaxis of invasive fungal infections for neutropenic patients; a study for 3 European countries. Blood (ASH Annual Meeting Abstracts), 106, 3133.
135. Powers, J.H. (2004) Empirical antifungal therapy in febrile neutropenic patients: caution about composite end points and the perils of P values. Clinical Infectious Diseases, 39, 1738 1739.
136. Prentice, H.G., Hann, I.M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., Pinkerton, C.R., Schey, S.A., Jacobs, F., Oakhill, A., Stevens, R.F., Darbyshire, P.J. Gibson, B.E.S. (1997) A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. British Journal of Haematology, 98, 711 718.
137. Prentice, H.G., Kibbler, C.C. Prentice, A.G. (2000) Towards a targeted, risk-based, antifungal strategy in neutropenic patients. British Journal Haematology, 110, 273 284.
138. Prentice, A.G., Glasmacher, A. Djulbegovic, B. (2006) In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy. British Journal Haematology, 132, 656 658.
139. Ratanatharathorn, V., Flynn, P.M., van Burik, J., McSweeney, P., Niederwieser, D. Kontoyiannis, D. (2002) Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis (RA) in bone marrow transplant (BMT) patients. Blood, 100, 627a (Abstract).
140. Reboli, A.C., Rotstein, C., Pappas, P.G., Chapman, S.W., Kett, D.H., Kumar, D., Betts, R., Wible, M., Goldstein, B.P., Schranz, J., Krause, D.S. Walsh, T.J. (2007) Anidulafungin versus fluconazole for invasive candidiasis. The New England Journal of Medicine, 356, 2472 2482.
141. Rex, J.H., Bennett, J.E., Sugar, A.M., Pappas, P.G., van der Horst, C.M., Edwards, J.E., Washburn, R.G., Scheld, W.M., Karchmer, A.W. Dine, A.P. (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. New England Journal of Medicine, 331, 1325 1330.
142. Rex, J.H., Pappas, P.G., Karchmer, A.W., Sobel, J., Edwards, J.E., Hadley, S., Brass, C., Vazquez, J.A., Chapman, S.W., Horowitz, H.W., Zervos, M., McKinsey, D., Lee, J., Babinchak, T., Bradsher, R.W., Cleary, J.D., Cohen, D.M., Danziger, L., Goldman, M., Goodman, J., Hilton, E., Hyslop, N.E., Kett, D.H., Lutz, J., Rubin, R.H., Scheld, W.M., Schuster, M., Simmons, B., Stein, D.K., Washburn, R.G., Mautner, L., Chu, T.C., Panzer, H., Rosenstein, R.B. Booth, J. (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clinical Infectious Diseases, 36, 1221 1228.
143. Rotstein, C., Bow, E.J., Laverdiere, M., Ioannou, S., Carr, D. Moghaddam, N. (1999) Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clinical Infectious Diseases, 28, 331 340.
144. Rotstein, C., Laverdiere, M., Marciniak, A. Ali, F. (2004) An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada. The Canadian Journal of Infectious Diseases & Medical Microbiology, 15, 277 284.
145. Santolaya, M.E., Rabagliati, R., Bidart, T., Paya, E., Guzman, A.M., Morales, R., Braun, S., Bronfman, L., Ferres, M., Flores, C., Garcia, P., Letelier, L.M., Puga, B., Salgado, C., Thompson, L., Tordecilla, J. Zubieta, M. (2005) Consensus: rational approach towards the patient with cancer, fever and neutropenia. Revista Chilena de Infectología, 22 (Suppl. 2 S79 S113.
146. Schuler, U., Bammer, S., Aulitzky, W.E., Binder, C., Bohme, A., Egerer, G., Sandherr, M., Schwerdtfeger, R., Silling, G., Wandt, H., Glasmacher, A. Ehninger, G. (2007) Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie, 30, 185 191.
147. Schwarzinger, M., Beauchamp, C., Maury, S., Pautas, C., Vekhoff, A., Farhat, H., Suarez, F., Hemery, F., Kuentz, M., Maison, P. Cordonnier, C. (2006) Empirical versus pre-emptive antifungal therapy in high-risk febrile neutropenic patients: an economic analysis. Blood (ASH Annual Meeting Abstracts), 108, 2021.
148. Silling, G., Fegeler, W., Roos, N., Essink, M. Buchner, T. (1999) Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses, 42 (Suppl. 2 101 104.
149. Singh, N. (2001) Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clinical Infectious Diseases, 33, 1692 1696.
150. Slavin, M.A., Osborne, B., Adams, R., Levenstein, M.J., Schoch, H.G., Feldman, A.R., Meyers, J.D. Bowden, R.A. (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. Journal of Infectious Diseases, 171, 1545 1552.
151. Slavin, M.A., Szer, J., Grigg, A.P., Roberts, A.W., Seymour, J.F., Sasadeusz, J., Thursky, K., Chen, S.C., Morrissey, C.O., Heath, C.H. Sorrell, A.T. (2004) Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Internal Medical Journal, 34, 192 200.
152. Stein, R.S., Kayser, J. Flexner, J.M. (1982) Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia. Cancer, 50, 2247 2251.
153. Storek, J., Espino, G., Dawson, M.A., Storer, B., Flowers, M.E. Maloney, D.G. (2000) Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood, 96, 3290 3293.
154. Subira, M., Martino, R., Rovira, M., Vazquez, L., Serrano, D. De La, C.R. (2003) Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Annals of Hematology, 82, 80 82.
155. Sullivan, K.M., Dykewicz, C.A., Longworth, D.L., Boeckh, M., Baden, L.R., Rubin, R.H. Sepkowitz, K.A. (2001) Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology/The Education Program of the American Society of Hematology, 392 421.
156. Trifilio, S., Verma, A. Mehta, J. (2004) Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplantation, 33, 735 739.
157. Ullmann, A.J., Lipton, J.H., Vesole, D.H., Chandrasekar, P., Langston, A., Tarantolo, S.R., Greinix, H., Morais de, A.W., Reddy, V., Boparai, N., Pedicone, L., Patino, H. Durrant, S. (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. The New England Journal of Medicine, 356, 335 347.
158. Uzun, O., Ascioglu, S., Anaissie, E.J. Rex, J.H. (2001) Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clinical Infectious Diseases, 32, 1713 1717.
159. Vardakas, K.Z., Michalopoulos, A. Falagas, M.E. (2005) Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. British Journal Haematology, 131, 22 28.
160. Verweij, P.E. (2005) Advances in diagnostic testing. Medical Mycology, 43 (Suppl. 1 S121 S124.
161. Verweij, P.E., Donnelly, J.P., Kullberg, B.J., Meis, J.F. De Pauw, B.E. (1994) Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection, 22, 81 85.
162. Viscoli, C., Castagnola, E., Van Lint, M.T., Moroni, C., Garaventa, A., Rossi, M.R., Fanci, R., Menichetti, F., Caselli, D., Giacchino, M. Congiu, M. (1996) Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. European Journal of Cancer, 32A, 814 820.
163. Viscoli, C., Castagnola, E., Caniggia, M., De Sio, L., Garaventa, A., Giacchino, M., Indolfi, P., Izzi, G.C., Manzoni, P., Rossi, M.R., Santoro, N., Zanazzo, G.A. Masera, G. (1998) Italian guidelines for the management of infectious complications in pediatric oncology: empirical antimicrobial therapy of febrile neutropenia. Oncology, 55, 489 500.
164. Walsh, T.J., Rubin, M., Hathorn, J., Gress, J., Thaler, M., Skelton, J., McKnight, J., Browne, M., Marshall, D. Cotton, D. (1991) Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. Archives of Internal Medicine, 151, 765 770.
165. Walsh, T.J., Finberg, R.W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R.N., Dummer, S., Schuster, M. Holcenberg, J.S. (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. New England Journal of Medicine, 340, 764 771.
166. Walsh, T.J., Pappas, P., Winston, D.J., Lazarus, H.M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., Schuster, M., Reboli, A., Wingard, J., Arndt, C., Reinhardt, J., Hadley, S., Finberg, R., Laverdiere, M., Perfect, J., Garber, G., Fioritoni, G., Anaissie, E. Lee, J. (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. New England Journal of Medicine, 346, 225 234.
167. Walsh, T.J., Groll, A., Hiemenz, J., Fleming, R., Roilides, E. Anaissie, E. (2004a) Infections due to emerging and uncommon medically important fungal pathogens. Clinical Microbiology and Infection, 10 (Suppl. 1 48 66.
168. Walsh, T.J., Teppler, H., Donowitz, G.R., Maertens, J.A., Baden, L.R., Dmoszynska, A., Cornely, O.A., Bourque, M.R., Lupinacci, R.J., Sable, C.A. dePauw, B.E. (2004b) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. New England Journal of Medicine, 351, 1391 1402.
169. Walsh, T.J., Raad, I., Patterson, T.F., Chandrasekar, P., Donowitz, G.R., Graybill, R., Greene, R.E., Hachem, R., Hadley, S., Herbrecht, R., Langston, A., Louie, A., Ribaud, P., Segal, B.H., Stevens, D.A., van Burik, J.A., White, C.S., Corcoran, G., Gogate, J., Krishna, G., Pedicone, L., Hardalo, C. Perfect, J.R. (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clinical Infectious Diseases, 44, 2 12.
170. Wenzel, R., Del, F.A., Kibbler, C., Rogers, T., Rotstein, C., Mauskopf, J., Morris, S., Schlamm, H., Troke, P. Marciniak, A. (2005) Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients 1. Journal of Antimicrobial Chemotherapy, 55, 352 361.
171. White, M.H., Bowden, R.A., Sandler, E.S., Graham, M.L., Noskin, G.A., Wingard, J.R., Goldman, M., van Burik, J.A., McCabe, A., Lin, J.S., Gurwith, M. Miller, C.B. (1998) Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clinical Infectious Diseases, 27, 296 302.
172. Wingard, J.R. (2004) Empirical antifungal therapy in treating febrile neutropenic patients. Clinical Infectious Diseases, 39 (Suppl. 1 S38 S43.
173. Wingard, J.R., White, M.H., Anaissie, E., Raffalli, J., Goodman, J. Arrieta, A. (2000) A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clinical Infectious Diseases, 31, 1155 1163.
174. Wingard, J.R., Herbrecht, R., Mauskopf, J., Schlamm, H.T., Marciniak, A. Roberts, C.S. (2007) Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transplant Infectious Disease, 9, 182 188.
175. Winston, D.J., Hathorn, J.W., Schuster, M.G., Schiller, G.J. Territo, M.C. (2000) A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patietns with cancer. American Journal of Medicine, 108, 282 289.
176. Wisplinghoff, H., Bischoff, T., Tallent, S.M., Seifert, H., Wenzel, R.P. Edmond, M.B. (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study 1. Clinical Infectious Diseases, 39, 309 317.
177. Yoshida, M. (2004) Guidelines for the management of deep mycosis in neutropenic patients. Nippon Ishinkin Gakkai Zasshi, 45, 209 215.
178. Zepelin, M.B., Kunz, L., Ruchel, R., Reichard, U., Weig, M. Gross, U. (2007) Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. Journal of Antimicrobial Chemotherapy, 60, 424 428.